利好突袭！深夜，暴涨！

Core Viewpoint - Pfizer is making a significant move to re-enter the weight loss drug market by acquiring Metsera for up to $7.3 billion, which could provide Pfizer with an established drug pipeline and clinical data, avoiding lengthy development times from scratch [2][7]. Group 1: Acquisition Details - Pfizer plans to acquire Metsera at a cash price of $47.50 per share, with potential additional payments based on performance milestones, bringing the total deal value to $7.3 billion [7]. - Metsera's leading drug candidate, MET-097i, is currently in Phase IIb trials, showing a weight reduction of 11.3% over 12 weeks with limited side effects [8]. - The acquisition fills a gap in Pfizer's portfolio for GLP-1 RA, long-acting amylin, and oral weight loss drugs, which are being developed by other companies like Novo Nordisk and Eli Lilly [8]. Group 2: Market Context - The U.S. stock market is experiencing a mixed trend, with major indices fluctuating; the Dow Jones is down 0.2%, while the Nasdaq is up 0.18% [9]. - Concerns about a potential market bubble are rising, with comparisons being made to the late 1990s tech bubble, despite ongoing improvements in corporate earnings [11][12]. - Analysts from Morgan Stanley suggest that the market may be underestimating the growth potential of U.S. corporate earnings, driven by operational leverage and suppressed demand [13].